US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

US IPOs and Secondary Offerings

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

IPOs and Secondary Offerings

Equity Capital Markets

Kestra Medical Technologies / Equity Capital Markets

<ul>
<li>Kestra Medical Technologies priced 11.9mm shares (upsized from 10.0mm) at $17.00 ($1 Above the $14-$16 range) and opened at $22.95 for a gain of 35%.</li>
<li>Kestra Medical Technologies (KMTS US) is the second medical device company to go public with success in 2025.</li>
<li>The equity capital markets area is still under scrutiny as a whole following the lackluster debuts of the two large IPOs in 2025.</li>
</ul>


Kestra Medical Technologies priced 11.9mm shares (upsized from 10.0mm) at $17.00 ($1 Above the $14-$16 range) and opened at $22.95 for a gain of 35%.
Kestra Medical Technologies (KMTS US) is the second medical device company to go public with success in 2025.
The equity capital markets area is still under scrutiny as a whole following the lackluster debuts of the two large IPOs in 2025.


Kestra Medical Technologies (KMTS): IPO Pops 35% at Open, Holds Gains Amidst Volatile Backdrop

<ul>
<li>Wearable defibrillator maker, Kestra Medical Technologies (KMTS US) is set to debut on Thursday (3/6) seeking a cash raise of up to $160 million and a valuation between $667m-$762.</li>
<li>The deal is considered well-oversubscribed from continued 1-on-1 conversions and high-quality engagements.</li>
<li>Given the financials and sector in which this company operates in and the strong backing (Bain Capital), we continue to believe this IPO will be well-received despite any market volatility.</li>
</ul>


Wearable defibrillator maker, Kestra Medical Technologies (KMTS US) is set to debut on Thursday (3/6) seeking a cash raise of up to $160 million and a valuation between $667m-$762.
The deal is considered well-oversubscribed from continued 1-on-1 conversions and high-quality engagements.
Given the financials and sector in which this company operates in and the strong backing (Bain Capital), we continue to believe this IPO will be well-received despite any market volatility.


Kestra Medical Technologies (KMTS): Medical Device IPO Story Easy to Digest Amidst Market Volatility

<ul>
<li>Kestra was founded in 2014 by Bain Capital private equity and leaders from the external (AED) and internal (ICD) defibrillation industries. </li>
<li>The company is seeking a valuation between $667m-$762m based on the $14-$16 range.</li>
<li>Given the financials, sector in which this company operates in and the strong backing, it is our early opinion that the IPO will likely be well-received.</li>
</ul>


Kestra was founded in 2014 by Bain Capital private equity and leaders from the external (AED) and internal (ICD) defibrillation industries. 
The company is seeking a valuation between $667m-$762m based on the $14-$16 range.
Given the financials, sector in which this company operates in and the strong backing, it is our early opinion that the IPO will likely be well-received.


Kestra Medical Technologies, Ltd (KMTS): Defibrillator Maker to Break IPO Thaw

<ul>
<li>They are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease.</li>
<li>As of January 31, 2025, the ASSURE WCD is actively being prescribed by more than 550 hospitals and has been worn by over 17,000 patients.</li>
<li>We anticipate this company to set terms (share size, price range) and debut in the last week of February or the first week of March. </li>
</ul>


They are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease.
As of January 31, 2025, the ASSURE WCD is actively being prescribed by more than 550 hospitals and has been worn by over 17,000 patients.
We anticipate this company to set terms (share size, price range) and debut in the last week of February or the first week of March. 


Kestra Medical Technologies, Ltd (KMTS): Peeking at the Prospectus of the Next Medical Device IPO

United States

Kestra Medical Technologies, Inc. operates as a wearable medical device and digital healthcare company. The Company develops cardiac recovery systems, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single unified solution. Kestra Medical Technologies serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Kestra Medical Technologies (KMTS US)

Kestra Medical Technologies (KMTS): IPO Pops 35% at Open, Holds Gains Amidst Volatile Backdrop

Kestra Medical Technologies IPO prices above range, gains 35% on debut, second successful medical device company to go public in 2025.

IPO Boutique

Kestra Medical Technologies (KMTS): Medical Device IPO Story Easy to Digest Amidst Market Volatility

Wearable defibrillator maker Kestra Medical Technologies set to debut with IPO seeking up to $160 million, backed by Bain Capital and expected to...

IPO Boutique

Kestra Medical Technologies, Ltd (KMTS): Defibrillator Maker to Break IPO Thaw

Kestra, founded in 2014 by Bain Capital and industry leaders, seeks a valuation of $667m-$762m in its upcoming IPO, expected to be well-received.

IPO Boutique

Kestra Medical Technologies, Ltd (KMTS): Peeking at the Prospectus of the Next Medical Device IPO

A wearable medical device company focused on improving cardiovascular patient outcomes is set to go public after gaining traction in hospitals and...

IPO Boutique

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Kestra Medical Technologies (KMTS): IPO Pops 35% at Open, Holds Gains Amidst Volatile Backdrop

​Kestra Medical Technologies IPO prices above range, gains 35% on debut, second successful medical device company to go public in 2025.

IPO Boutique

Kestra Medical Technologies (KMTS): Medical Device IPO Story Easy to Digest Amidst Market Volatility

​Wearable defibrillator maker Kestra Medical Technologies set to debut with IPO seeking up to $160 million, backed by Bain Capital and expected to...

IPO Boutique

Kestra Medical Technologies, Ltd (KMTS): Defibrillator Maker to Break IPO Thaw

​Kestra, founded in 2014 by Bain Capital and industry leaders, seeks a valuation of $667m-$762m in its upcoming IPO, expected to be well-received.

IPO Boutique

Kestra Medical Technologies, Ltd (KMTS): Peeking at the Prospectus of the Next Medical Device IPO

​A wearable medical device company focused on improving cardiovascular patient outcomes is set to go public after gaining traction in hospitals and...

IPO Boutique

Kestra Medical Technologies IPO prices above range, gains 35% on debut, second successful medical device company to go public in 2025.

Wearable defibrillator maker Kestra Medical Technologies set to debut with IPO seeking up to $160 million, backed by Bain Capital and expected to...

Kestra, founded in 2014 by Bain Capital and industry leaders, seeks a valuation of $667m-$762m in its upcoming IPO, expected to be well-received.

A wearable medical device company focused on improving cardiovascular patient outcomes is set to go public after gaining traction in hospitals and...